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Abstract
The prevalence of undiagnosed cardiac involvement in granulomatosis with polyangiitis (GPA) is unknown. In this prospec-
tive study we investigated the utility of cardiovascular magnetic resonance (CMR) to identify myocardial abnormalities in 
GPA and their correlation with disease phenotype. Twenty-six patients with GPA and no cardiovascular disease or diabetes 
mellitus underwent contrast-enhanced CMR, including late gadolinium-enhancement (LGE), T1-mapping for native T1 
and extra-cellular volume (ECV) quantification for assessment of myocardial fibrosis, cine imaging and tissue tagging for 
assessment of left ventricular (LV) function. Twenty-five healthy volunteers (HV) with comparable age, sex, BMI and arterial 
blood pressure served as controls. Patients with GPA had similar cardiovascular risk profile to HV. A focal, non-ischaemic 
LGE pattern of fibrosis was detected in 24% of patients and no controls (p = 0.010). Patients with myocardial LGE were 
less frequently PR3 ANCA (7% vs 93%, p = 0.007), and had involvement of the lower respiratory tract and skin. LGE scar 
mass was higher in patients presenting with renal involvement. Native T1 and ECV were higher in patients with GPA than 
HV; ECV was higher in those with relapsing disease, and native T1 was inversely associated with PR3 ANCA (β = − 0.664, 
p = 0.001). Peak systolic strain was slightly reduced in GPA compared to controls; LV ejection function was inversely cor-
related with disease duration (β = − 0.454, p = 0.026). Patients with GPA have significant myocardial abnormalities on CMR. 
ANCA, systemic involvement and disease severity were associated with myocardial fibrosis. CMR could be a useful tool for 
risk stratification of myocardial involvement in GPA.
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Introduction
Granulomatosis with polyangiitis (GPA), a systemic inflam-
matory disease, is an ANCA-associated small-vessel vas-
culitides (AAV) [1] with significant morbidity and mortal-
ity [2, 3]. Recent epidemiological studies have highlighted 
the increased frequency of cardiovascular (CV) events in 
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patients with AAV and GPA [4–6], with resulting higher 
death rates from CV disease (CVD) [7, 8].
The increased morbidity and mortality due to CVD in 
patients with immune-mediated and inflammatory diseases 
(IMID) is thought primarily to be due to accelerated ath-
erosclerosis [9]. However, primary myocardial involvement 
due to inflammation unrelated to typical atherosclerotic 
processes has been described in patients with systemic vas-
culitides [10–14], despite modern era immunosuppression 
[15].
Despite clear evidence of adverse CV outcomes in GPA, 
the underlying pathogenesis for cardiovascular involvement 
in GPA is poorly understood. Inflammatory myocardial 
involvement is probably underestimated as it is often not 
clinically looked for or detected until a CV event occurs. 
A retrospective echocardiography study revealed CV 
abnormalities related to GPA in up to 36% of patients [16]. 
Although the impact of subclinical CVD in GPA is not yet 
known, in the general population it has been associated with 
an increased risk of CV events in large population studies 
[17, 18].
Cardiovascular magnetic resonance (CMR) is a non-inva-
sive imaging technique that is increasingly used to detect 
CVD in patients with IMID [19] with clear advantages over 
echocardiography. In particular, CMR is highly accurate 
and reproducible for the evaluation of left ventricular (LV) 
volumes, function and mass, and for advanced myocardial 
tissue characterization [20]. In contrast to echocardiography, 
CMR imaging with late gadolinium enhancement (LGE) has 
the ability to detect focal myocardial fibrosis [21]. Myocar-
dial T1 mapping methods with calculation of extracellular 
volume fraction (ECV) can be useful in detecting oedema 
and early subclinical, diffuse myocardial fibrosis, with good 
correlation to histological findings of myocardial fibrosis in 
various clinical contexts [22, 23].
Although preliminary reports suggest that CMR is val-
uable in AAV [24, 25], a systematic assessment of GPA 
patients with CMR imaging has not been performed. The 
primary objective of this single-centre, observational, pro-
spective study was to determine the prevalence and pattern 
of subclinical cardiac involvement in GPA as detected by 
CMR imaging; the secondary objective was to describe 
which GPA disease characteristics were associated with 
cardiac abnormalities detected by CMR.
Methods
Study design
This study was a single-centre, observational, cross-sec-
tional feasibility study. Consecutive patients between 18 and 
80 years attending the Vasculitis clinic at Leeds Teaching 
Hospitals NHS Trust (LTHT) were approached to enter the 
study. In addition to a comprehensive clinical evaluation at 
baseline, participants underwent contrast-enhanced CMR. 
All patients gave their written, informed consent to take part 
in the study with approval of the National Research Ethics 
Service (10/H1306/88).
Study population
All patients invited to participate met the 2012 revised 
Chapel Hill Consensus nomenclature for vasculitis [26]. 
Selection criteria was age 18-80, complete remission with a 
Birmingham Vasculitis Activity Score (BVAS) < 0 following 
induction therapy and no prior diagnosis of CVD or diabe-
tes mellitus to minimise the possibility of subclinical CVD 
occurring due to multimorbidity. Controls were identified 
from a previously recruited pool of 80 healthy volunteers 
(HV) with no diabetes mellitus (DM) and no known CVD 
with their imaging assessments recorded using the same 
CMR scanner as the vasculitis subjects. The controls were 
frequency-matched to GPA patients according to age, sex, 
BMI and mean arterial pressure (MAP). All participants 
(both vasculitis subjects and HV) were excluded if they had 
DM, uncontrolled arterial hypertension or a prior diagnosis 
of CVD including: heart failure (HF), coronary artery dis-
ease (CAD), cerebrovascular accident (CVA), valve disease, 
and peripheral arterial disease (PAD).
Clinical data
Comprehensive demographic and clinical data were col-
lected including the following CV risk factors: Hyperten-
sion was defined as a systolic blood pressure (SBP) of at 
least 140 mmHg and/or a diastolic blood pressure (DBP) 
of at least 90 mmHg, and/or pharmacologically treated 
blood pressure of unknown cause. Obesity was identified as 
a BMI ≥ 30 kg/m2. Dyslipidaemia was defined as levels of 
total serum cholesterol (TC) above 190 mg/dl and/or triglyc-
erides (TG) above 150 mg/dl, or pharmacologically treated 
high lipid serum levels. To assess renal function, we consid-
ered the glomerular filtration rate (GFR) estimated with the 
chronic kidney disease-epidemiology (CKD-EPI) equation.
GPA assessment was recorded as disease phenotype 
(organ involvement, disease duration, ANCA status, number 
of relapses), past and current medications, disease activity 
assessed by BVAS, 3rd version [27] and damage assessed 
by the Vasculitis Damage Index (VDI) [28].
Disease relapse was defined as reappearance or worsening 
of vasculitis symptoms requiring an increase of the current 
treatment or introduction of additional immunosuppressive 
medication.
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Biochemical assessment
Blood samples were collected in close proximity to the day 
of CMR assessment. The following measurements were per-
formed: full blood counts (FBC), creatinine (P-Cr), blood 
urea nitrogen (BUN), anti-neutrophil cytoplasm antibodies 
(ANCA), C-reactive protein (CRP), and erythrocyte sedimen-
tation rate (ESR).
CMR protocol and analysis
CMR studies were performed on a 3T Philips Achieva MR 
system. Trained CMR radiographers directed the scan, and 
image analysis was performed in accordance with recognised 
reporting standards [29] and using established and validated 
protocols [30]. The full CMR protocol included resting wall 
motion and LV function, tissue tagging, aortic distensibility, 
LGE, native and post contrast T1 mapping for ECV quanti-
fication. Native T1 and ECV were measured in areas with-
out scar on LGE. Comprehensive and detailed descriptions 
of each analysis and their interpretation are available in the 
on-line supplementary file. LGE analysis was performed by 
two independent assessors (RBD, JG) and quantified using 
the Full Width Half Maximum (FWHM) technique. Aortic 
distensibility was defined as decreased if below the 5th centile 
of a reference population [31]. Normal ranges for ECV was 
defined as increased if above the upper limit of a reference 
range previously reported [32].
Statistical analysis
As a feasibility study, formal power calculation for determin-
ing sample size was not indicated. Descriptive statistics are 
reported. Continuous data are represented by median [25th, 
75th percentile]. Categorical data are described as absolute 
number (percentage). Between groups comparisons of con-
tinuous variables, including differences between GPA patients 
and heathy volunteers, were performed with the Mann–Whit-
ney U test. Associations between dichotomous variables 
were assessed by Chi squared test or Fisher’s exact test where 
appropriate. The strength of the association between disease 
characteristics, CV risk factors and continuous CMR meas-
ures were assessed by the Spearman’s rho (r) coefficients. The 
statistical package IBM SPSS Statistics for Windows, Version 
20.0 (Armonk, New York, USA) was used for the matching 
procedure and statistical analysis. Statistical significance was 
considered for a P value of 0.05 or less.
Results
Patient disposition
Sixty-four patients were consecutively approached between 
October 2017 and April 2018 from which 32 patients con-
sented to enter the study and 26 patients proceeded to CMR 
assessment (patient flow pathway is illustrated in Fig. 1). 
One patient did not receive gadolinium-based contrast due 
to their inability to tolerate the intravenous (IV) infusion.
Baseline characteristics of study participants
The baseline patient characteristics are reported in Table 1. 
Median age of GPA patients was 58 years and all but one of 
the patients were white British. All patients had established 
disease as per study protocol, three-quarters were ANCA 
positive, and almost all received either CYC or RTX for 
induction of remission. ENT, pulmonary and renal involve-
ment was frequent (over 60%), and the majority had suffered 
at least one disease relapse.
With regards to CV profile (Table  2), 19/26 (73%) 
patients had at least one (median 1 [0, 3]) traditional CV 
risk factor. Approximately half of the study population was 
taking CV medications. As per protocol, heathy volunteers 
did not differ significantly from patients with GPA when 
compared for age, BMI, BP and the male-to-female ratio.
Comparison of CMR measures between GPA subjects 
and heathy volunteers
Compared to heathy volunteers, GPA patients had smaller 
chamber volumes and decreased LV mass. Native T1 and 
ECV were significantly higher in GPA than controls (6/25 
patients had increased ECV, no HV had increased ECV). 
LGE was detected in 8/25 (32%) GPA patients and in no 
controls. No GPA patient had LGE in a pattern of enhance-
ment suggesting ischaemic-mediated myocardial damage. 
A focal pattern of fibrosis was seen in all GPA patients with 
LGE. LGE most commonly involved the basal LV and lat-
eral segments and was located in the midwall to subepi-
cardial layer in 6/8 (75%) patients (Table 3; Fig. 2). Two 
patients had evidence of scarring uniquely in the inferior 
wall and right ventricle insertion point (RVIP). However, the 
pathogenesis and clinical relevance of LGE at RVIP remains 
poorly understood, and is generally believed to be a nonspe-
cific finding in CMR studies, although a few reports suggest 
that RVIP-LGE may be related to pulmonary hypertension 
[33–36]. Hence, when subsequently we analysed correla-
tions and associations of clinical variables with LGE, we 
chose to exclude the two patients with isolated RVIP-LGE, 
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as we believed it had a low likelihood to represent a dis-
tinct pattern of myocardial fibrosis in our patients with 
GPA. There was no difference in LV EF between patients 
with GPA and heathy volunteers (Table 3), and values for 
strain were within normal range both in patients and healthy 
volunteers.
Relationship between traditional CV risk factors 
and CMR measures
In the whole study population, diastolic BP was associated 
with LVEDV index independent of age and sex (β = − 0.29, 
p = 0.042). In patients with GPA, the descending aorta dis-
tensibility was decreased compared to reference values in 
19/26 (73%; 100% of females and 50% of males) and cor-
related inversely with age (r = − 0.532, p = 0.005), LGE scar 
mass (r = − 0.810, p = 0.015), MAP (r = − 0.519, p = 0.007) 
and SBP (r = − 0.650, p < 0.001). We did not find signifi-
cant associations between other CMR measures and CV risk 
factors.
Associations of CMR measures with disease 
characteristics of GPA
LVESV index was associated with PR3 ANCA status 
(23 ml/m2 [21, 34] in PR3 ANCA negative vs 31 ml/m2 
(26, 38) in PR3 ANCA positive patients, p = 0.032) and 
correlated with disease duration (r = 0.420, p = 0.033). 
LVEF was positively correlated to disease duration as 
well (r = − 0.429, p = 0.029). Native T1 was associated 
with PR3 ANCA status (1268 ms [1248, 1337]) in PR3 
ANCA negative vs 1212 ms [1196, 1236] in PR3 ANCA 
positive patients, p < 0.001). ECV was significantly higher 
in GPA patients with relapsing disease (25.6% [24.2, 29.8] 
vs 24.1% [22.1, 25.8], p = 0.037). All results via univari-
ate analysis.
Characteristics of GPA patients 
with and without LGE
Patients with myocardial LGE (LGE+) were more fre-
quently PR3 ANCA negative (93% vs 7%, p = 0.007), 
and more likely to have involvement of the lower respira-
tory tract (75% vs 25%, p = 0.097) and skin (63% vs 38%, 
p = 0.087). No significant differences were noted in previ-
ous or current immune-suppressive regimes, although there 
was a trend to less frequent use of RTX in LGE + patients 
(25% vs 75%, p = 0.081). Native T1 values were higher in 
LGE + patients: 1259 ms [1234, 1284] vs 1220 ms [1197, 
1270], p = 0.023, and ECV was only modestly increased in 
this group. Patients with GPA and LGE + had a significantly 
higher LV mass/LVEDV ratio: 0.64 [0.60, 0.67] vs 0.52 
[0.47, 0.63], p = 0.043. The LGE scar mass was associated 
with renal involvement: 0.82 g [0.80, 1.09] vs 2.98 g [1.58, 
4.51], p = 0.036.
Fig. 1  Flow chart of GPA 
patients participating in the 
study
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Discussion
To our knowledge, this is the first prospective, multi-para-
metric CMR imaging study in GPA patients with no previ-
ous diagnosis of CVD or diabetes mellitus. As a feasibility 
study, it was not powered to detect significant associations 
between CMR outcomes and GPA disease characteristics, 
however we believe our results provide new insights into 
the prevalence and distribution of primary subclinical 
CVD in GPA and align with our findings using similar 
CMR protocols in other IMID cohorts [38, 39].
Few studies have investigated cardiac involvement in 
GPA using CMR imaging. One retrospective, non-con-
trolled study with 1.5T CMR by the French Vasculitis 
Study Group [24] recruited over an 8-year period and did 
not comprehensively exclude concomitant CVD. Other 
investigators [25] performed a 1.5T CMR imaging with 
T1 and T2 mapping study in consecutive AAV patients 
and age and sex matched healthy volunteers. The authors 
reported a pooled analysis of AAV which included several 
patients with eosinophilic GPA (EGPA), a subset of AAV 
characterised by a distinct type of myocardial involvement. 
Current management guidelines of GPA do not recom-
mend CV imaging at disease onset nor during follow up, 
although CVD is a major determinant of mortality in AAV 
[40], however the specific cardiac abnormalities associated 
with GPA have not been defined.
The primary finding of this feasibility study is the detec-
tion of myocardial fibrosis in approximately one-third of 
GPA patients, in line with previous reports [24, 25, 41]. 
LGE corresponds to areas of myocardial fibrosis as shown 
by comparison with histopathology [42], and its presence 
has prognostic value in ischaemic and non-ischaemic car-
diomyopathies [43, 44]. The myocardial LGE can show dif-
ferent patterns according to diverse pathology; trans-mural 
LGE is typical of myocardial infarction whilst non-ischemic 
conditions associate with focal enhancement. Interestingly, 
the LGE seen in our GPA patients was focal and distributed 
subepicardially or at the mid-wall in most cases, in keeping 
with a non-ischaemic cause. Furthermore, this fibrotic tissue 
was frequently found in the lateral segments.
The presence of LGE was not associated with tradi-
tional CV risk factors, and we minimised the likelihood of 
underlying undiagnosed CAD by excluding GPA patients 
at highest risk (i.e. those with previous CV events and/or 
with DM). LGE was associated with PR3 ANCA negativity 
and also renal involvement, suggesting a potential relation-
ship between myocardial fibrosis in GPA and specific dis-
ease characteristics. This finding is of clinical interest as the 
presence or absence of LGE on CMR could, in the future, 
help with CVD risk stratification in patients with GPA [19]. 
Whether myocardial LGE is associated with increased risk 
of relapse or disease severity needs to be addressed with 
further research.
Native T1 and ECV are indicative of a diffuse intramyo-
cardial fibrosis/inflammation, including in the absence of 
infarction [45]. Native T1 and ECV values were slightly 
elevated in patients with GPA when compared to healthy 
volunteers, in keeping with previous reports [25]. We only 
included patients with established GPA, suggesting that a 
degree of cardiac inflammation is present throughout the 
GPA disease continuum, and, in our cohort, an association 
Table 1  Disease characteristics of patients with AAV
Median (25th, 75th percentile) values are presented unless stated oth-
erwise
ANCA Anti-neutrophil cytoplasmic antibody, BMI body mass index, 
BP blood pressure, BVAS Birmingham Vasculitis Activity Score, CV 
cardiovascular disease, CRP C-reactive protein, CYC cyclophospha-
mide, ESR erythrocyte sedimentation rate, RTX rituximab, VDI vas-
culitis damage index
Disease characteristics GPA patients (n = 26)
Disease duration (year) 8 (2, 12)
Biopsy obtained [n(%)] 20 (77)
ANCA-positive at diagnosis [n (%)] 20 (77)
 IFI 22 (85)
 ANCA PR3 15 (58)
 ANCA MPO 6 (23)
Organ involvement [n (%)]












Relapsing disease [n (%)] 17 (65)
 Last relapse (months) 42 (10,91)




 RTX last cycle (months) 28 (9, 50)
 CYC last cycle (months) 15 (7, 77)
 Prednisolone 11 (42)
  Prednisolone dose (mg daily) 5 (5, 10)
Disease activity
 BVAS 2 (1, 4)
  Remission (BVAS = 0) [n (%)] 6 (23)
 VDI 1 (0, 1)
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between native T1 and vasculitis-related damage (VDI) and 
inflammation (CRP).
Assessment of patients with GPA using CMR may also 
reveal LV remodelling, with characteristics similar to that 
seen in our previously reported IMID cohorts [37, 38]. 
LV volumes were decreased in GPA patients compared 
to healthy volunteers, similar findings have been reported 
with echocardiography in RA patients, often in association 
with a concentric LV geometry and subclinical LV dysfunc-
tion [46–48]. Interestingly, LV mass in GPA patients was 
also significantly lower than controls and below published 
normal ranges [45]; which has been previously reported in 
patients with AAV [25] and also systemic sclerosis [39] and 
RA [38], implying the presence of inflammatory myocardial 
involvement across the IMID spectrum.
Cardiac abnormalities are common in GPA patients and 
the likelihood of cardiac damage may be highest in the early 
stages of the disease [49, 50]. In this study we report pri-
mary, non-ischaemic myocardial abnormalities in asympto-
matic GPA patients with well controlled disease, suggesting 
that subclinical cardiac pathology cay occur in GPA patients 
despite the absence of cardiac signs or symptoms [8]. The 
clinical implications of this remain to be determined. Addi-
tionally, in our study, a longer disease duration was asso-
ciated with several measures of LV systolic dysfunction, 
underlining the importance of aiming for disease remission 
rather than low disease activity in GPA. In the future, dis-
ease activity indexes could be used to aid the prediction of 
future CV events and CVD-related mortality in patients with 
GPA [51].
Clinical implications and novelties
In this study, we prospectively demonstrated the feasibility 
and usefulness of CMR in GPA. Our data show that patients 
with GPA have both subclinical inflammation and fibrosis 
detected by CMR mapping techniques, despite being free 
of overt cardiac disease and vasculitic symptoms. ECV was 
associated with relapsing disease, suggesting that a clini-
cally non-resolving vasculitis may cause active myocardial 
inflammation. Moreover, we demonstrated that myocardial 
fibrosis was present even when ANCA were not detectable in 
patients with skin and pulmonary involvement from vasculi-
tis. Hence, our data could help to define those patients clini-
cally at a higher risk of cardiac involvement. T1 mapping, 
ECV and LGE should all be assessed for the characterization 
of myocardial involvement in GPA, as they provide comple-
mentary information about diffuse myocardial involvement 
compared to one technique alone. Whether such alterations 
are reversible or can progress to additional damage should 
be addressed in further research.
Study strengths and limitations
Major strengths include: first, the pre-defined protocol with 
3.0T CMR imaging, which informed rheumatologists to 
perform T1 mapping, LGE and ECV to detect myocardial 
involvement in GPA; second, the inclusion of controls also 
matched for arterial BP, which allowed to exclude hyperten-
sive cardiac alterations; third, the multidisciplinary nature 
of our research group, which includes clinician-researchers 
experienced in both vasculitis and cardiac imaging; and last, 
we fully described the vasculitis status and characteristics 
and their associations with CMR abnormalities. Finally, 
our study included mostly patients with low disease activity 
(median BVAS = 2), actually showing that subclinical myo-
cardial involvement can be detected even in GPA patients 
without active significant organ involvement.
The most important limitation of our study is a small 
size, though it is comparable to previous research groups 
Table 2  Cardiovascular risk 
factors of study population
Median (25th, 75th percentile) values are presented unless stated otherwise
BMI body mass index, BP blood pressure, CV cardiovascular disease, CRP C-reactive protein, ESR eryth-
rocyte sedimentation rate, LV left ventricular, MAP mean arterial pressure, MCV mean corpuscular volume, 
NA data not available
Cardiovascular risk factors 
and medications
GPA patients (n = 26) Heathy volunteers (n = 25) P value
Age (years) 58 (45, 66) 61 (51, 66) 0.665
Female sex [n (%)] 12 (46) 7 (28) 0.180
Smoking status (ever) 5 (19) 0 (0) 0.021
BMI [kg/m2] 28.7 (24.3, 30.8) 27.0 (23.9, 28.9) 0.175
Obese [n (%)] 9 (35) 5 (20) 0.242
Hypertension [n (%)] 10 (39) 7 (28) 0.556
 SBP [mmHg] 137 (121, 141) 122 (117, 142) 0.127
 DBP [mmHg] 76 (67, 82) 72 (61, 79) 0.279
 MAP [mmHg] 94 (86, 103) 90 (82, 96) 0.152
Dyslipidaemia [n (%)] 9 (35) NA NA
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reporting on the same topic. We advocate multi-centric 
studies to increment the study population and to validate 
our results. Another limitation is that we could not entirely 
exclude CAD, yet we excluded a priori participants with 
overt CVD, diabetes or uncontrolled hypertension. Finally, 
a validation procedure, such as endomyocardial biopsy, 
was not performed. Endomyocardial biopsy was not 
offered to patients as they all had preserved LV-EF and 
were all asymptomatic for cardiac symptoms. However, 
endomyocardial biopsy has several limitations, including 
low sensibility, lowering its diagnostic benefit.
Conclusion
This study describes CMR imaging findings in patients 
with established stable GPA. Myocardial fibrosis and 
abnormal LV geometry were more common in GPA 
patients than in matched healthy controls, and corre-
late with certain disease characteristics. Although the 
prognostic implications of our results are yet to be fully 
understood, our group has reported on the frequency and 
severity of cardiac abnormalities in a population of GPA 
Table 3  Comparison of CMR 
characteristics between GPA 
patients and heathy volunteers
Median (25th, 75th percentile) values are presented unless stated otherwise
Left and right ventricle volumes are indexed by body surface area
CMR cardiovascular magnetic resonance, ECV extracellular-volume fraction, EDV end-diastolic volume, 
ESV end-systolic volume, LGE late gadolinium enhancement, LV left ventricular, LV EF left ventricular 
ejection fraction, NA data not available, RVIP right ventricle insertion point
a Data available in 24/26 GPA patients
b Data available in 25/26 GPA patients
CMR measures GPA patients (n = 26) Heathy volunteers (n = 25) P value
LV volumes and mass
 LV EDV index (mL/m2) 69 (61, 84) 79 (70, 89) 0.105
 LV ESV index (mL/m2) 28 (23, 37) 32 (28, 39) 0.122
 LV mass index (g/m2) 37 (42, 47) 50 (42, 56) 0.014
 LV mass/LVEDV, g/mL 0.59 (0.48, 0.66) 0.59 (0.54, 0.66) 0.486
LV function
 LV EF (%) 59 (56, 63) 58 (53, 62) 0.351
 LV peak systolic strain
  Base -0.19 (-0.21, -0.16) -0.21 (-0.22, -0.19) 0.017
  Mid -0.21 (-0.23, -0.20) -0.22 (-0.23, -0.20) 0.298
  Apex -0.21 (-0.23, -0.16) -0.23 (-0.25, -0.20) 0.101
 Torsion (°) 12.3 (9.2, 14.5) 13.8 (11.6, 16.0) 0.086
 Peak  twista 14.1 (9.0, 15.7) 14.1 (11.7, 17.7) 0.222
Myocardial tissue characterization
 Native T1 (ms) 1225 (1199, 1255) 1203 (1185, 1233) 0.006
 Extracellular volume (%)b 25.0 (23.3, 27.2) 23.6 (20.5, 25.1) 0.009
 Increased extracellular volume [n (%)] 6/25 (24) 0 (0) 0.022
 LGE [n (%)]b 8/25 (32) 0/25 (0) 0.010
 LGE distribution
  Subepicardial 4/8 (50) 0/25 (0) NA
  Midwall 2/8 (25) 0/25 (0) NA
  RVIP 2/8 (25) 0/25 (0) NA
 LGE segments
  Basal antero-lateral 4/8 (50) 0/25 (0) NA
  Basal infero-lateral 3/8 (38) 0/25 (0) NA
  Basal antero-septal 1/8 (13) 0/25 (0) NA
 LGE scar tissue (g) 1.25 (0.81, 2.63) 0 (0, 0) NA
Aortic distensibility
 Descending aorta  (10−3  mmHg−1) 2.95 (2.29, 3.64) NA NA
  Abnormal stiffness [n (%)] 19/26 (73) NA NA
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patients which will inform future studies aimed at evalu-
ating the management of cardiac involvement in patients 
with GPA.
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Fig. 2  CMR imaging from a single patient with GPA: SSFP cine 
imaging (a), Native T1 map with colour scale from 1000 ms (purple) 
to 2000 ms (yellow) (b), grid tags at end diastole (c) and end systole 
(d) and late gadolinium enhancement imaging in short (e) and long 
axis (f) with focal fibrosis shown by red arrow
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